> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Real-time glucose monitoring modelled at £5,943 per quality-adjusted life-year
- URL: https://www.coios.me/real-time-glucose-monitoring-modelled-at-5-943-per-quality/
- Published: 2026-11-18T13:14:47.000Z
- Updated: 2026-11-18T13:55:51.000Z
- Description: A lifetime model gave £5,943 per QALY for FreeStyle Libre real-time monitoring over finger-prick testing in type 2 diabetes.
- Author: Daniel Ryan
- Tags: Data, models and systems, Value in health, Obesity, diabetes and GLP-1, United Kingdom, #peer-reviewed, #new, #item, #source-2026-11, #score-74

The study assessed the cost-effectiveness of FreeStyle Libre real-time continuous glucose monitoring (rtCGM) against self-monitoring of blood glucose (SMBG). Adults had type 2 diabetes above glucose target, on basal insulin plus an SGLT-2 inhibitor and/or GLP-1 agonist. Trial EQ-5D-5L and resource-use data fed the IQVIA CORE Diabetes Model for lifetime projections from the UK NHS perspective. At 32 weeks there was no significant difference in QALYs (-0.015) or costs (£254). Over a lifetime, rtCGM gained 0.730 QALYs for £4,341 more, an ICER of £5,943 per QALY. The lifetime result rests on modelled HbA1c benefits, with at least 4 years of maintained benefit needed for cost-effectiveness.

*Why it is interesting: Within the trial, QALYs and costs did not differ significantly, yet the lifetime model gave a low cost per QALY. The result depends on the HbA1c benefit being assumed to last at least 4 years.*

Source

[Diabetes, Obesity and Metabolism, 15 November 2026](https://doi.org/10.1111/dom.71476?ref=coios.me)

DOI

10.1111/dom.71476

Type

Peer-reviewed article

Design

Within-trial economic evaluation alongside an RCT (EQ-5D-5L and resource use at 16 and 32 weeks) extrapolated to lifetime using the IQVIA CORE Diabetes Model, UK NHS perspective, 3.5% discount

Verdict

New finding

Driver

[Value in health](https://www.coios.me/d-health-economics/)

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)